DE60222015T2 - Ccr-3-rezeptorantagonisten vii - Google Patents

Ccr-3-rezeptorantagonisten vii Download PDF

Info

Publication number
DE60222015T2
DE60222015T2 DE60222015T DE60222015T DE60222015T2 DE 60222015 T2 DE60222015 T2 DE 60222015T2 DE 60222015 T DE60222015 T DE 60222015T DE 60222015 T DE60222015 T DE 60222015T DE 60222015 T2 DE60222015 T2 DE 60222015T2
Authority
DE
Germany
Prior art keywords
alkyl
compound
formula
hydrogen
chlorobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60222015T
Other languages
German (de)
English (en)
Other versions
DE60222015D1 (de
Inventor
Daisy Joe Palo Alto DU BOIS
Beihan Santa Clara WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60222015D1 publication Critical patent/DE60222015D1/de
Application granted granted Critical
Publication of DE60222015T2 publication Critical patent/DE60222015T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE60222015T 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii Expired - Fee Related DE60222015T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33481901P 2001-11-30 2001-11-30
US334819P 2001-11-30
PCT/EP2002/012997 WO2003045917A2 (en) 2001-11-30 2002-11-20 Ccr-3 receptor antagonists vii

Publications (2)

Publication Number Publication Date
DE60222015D1 DE60222015D1 (de) 2007-10-04
DE60222015T2 true DE60222015T2 (de) 2008-06-05

Family

ID=23308965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222015T Expired - Fee Related DE60222015T2 (de) 2001-11-30 2002-11-20 Ccr-3-rezeptorantagonisten vii

Country Status (16)

Country Link
US (1) US7019007B2 (https=)
EP (1) EP1453804B1 (https=)
JP (1) JP2005518364A (https=)
KR (1) KR100579352B1 (https=)
CN (1) CN1296356C (https=)
AR (1) AR037586A1 (https=)
AT (1) ATE370932T1 (https=)
AU (1) AU2002356694A1 (https=)
BR (1) BR0214611A (https=)
CA (1) CA2468402A1 (https=)
DE (1) DE60222015T2 (https=)
ES (1) ES2291539T3 (https=)
MX (1) MXPA04004980A (https=)
PL (1) PL373275A1 (https=)
RU (1) RU2004120065A (https=)
WO (1) WO2003045917A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034257A1 (es) * 2000-06-30 2004-02-18 Du Pont Pharm Co Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
WO2004041777A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
JP4384635B2 (ja) * 2003-06-30 2009-12-16 住友化学株式会社 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法
US7541468B2 (en) * 2004-06-10 2009-06-02 Bristol-Myers Squibb Company Process of preparing N-ureidoalkyl-piperidines
US8883791B2 (en) * 2010-09-29 2014-11-11 Intervet Inc. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953005A (en) * 1961-02-24 1964-03-18 Soc Ind Fab Antibiotiques Sifa Substituted n-phenylethyl-n-phenyl-piperazines
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6455528B1 (en) * 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JP2002532427A (ja) * 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのn−ウレイドアルキルピペリジン
EP1140087A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001007427A1 (en) * 1999-07-28 2001-02-01 Daiichi Radioisotope Laboratories, Ltd. Vesamicol piperazine derivatives and drugs containing the same
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
ATE370932T1 (de) 2007-09-15
PL373275A1 (en) 2005-08-22
WO2003045917A3 (en) 2003-10-09
JP2005518364A (ja) 2005-06-23
CN1296356C (zh) 2007-01-24
CA2468402A1 (en) 2003-06-05
CN1599721A (zh) 2005-03-23
US7019007B2 (en) 2006-03-28
DE60222015D1 (de) 2007-10-04
KR100579352B1 (ko) 2006-05-12
AR037586A1 (es) 2004-11-17
EP1453804B1 (en) 2007-08-22
AU2002356694A1 (en) 2003-06-10
MXPA04004980A (es) 2004-08-11
WO2003045917B1 (en) 2003-12-04
RU2004120065A (ru) 2005-05-27
US20030153578A1 (en) 2003-08-14
BR0214611A (pt) 2004-09-14
KR20040062663A (ko) 2004-07-07
WO2003045917A2 (en) 2003-06-05
EP1453804A2 (en) 2004-09-08
ES2291539T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
DE69833073T2 (de) CCR-3-Rezeptor-Antagonisten
DE69921351T2 (de) 4-Aroyl-Piperidin-CCR-3 Rezeptorantagonisten III
US6342509B1 (en) Piperidine quaternary salts- CCR- 3 receptor antagonists
DE19955794A1 (de) Pyrrolidin-Derivate-CCR-3-Rezeptor-Antagonisten
DE60221275T2 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE60222015T2 (de) Ccr-3-rezeptorantagonisten vii
US6977265B2 (en) Piperidine CCR-3 receptor antagonists
US20040014775A1 (en) 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists
US7049317B2 (en) CCR-3 receptor antagonists
DE69918113T2 (de) Hydroxamsäurederivate als Inhibitoren der Herstellung von menschlichem CD23 und der TNF-Freisetzung
AU2002352123A1 (en) N-ureido-piperidines as antagonists viii for ccr-3 receptor
DE60130684T2 (de) Substituierte pyrrolidine als ccr-3-rezeptorantagonisten
AU2002339504A1 (en) CCR-3 receptor antagonists V

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee